Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For diabetes mellitus. Sold as Fiasp, Fiasp Flextouch, Fiasp Penfill. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Insulin Aspart (sold as Fiasp, Fiasp Flextouch, Fiasp Penfill), first approved Sep 29, 2017, with 3 new uses approved and 0 published complete response letters.
First approved: Sep 29, 2017
Applications: 1
New uses approved: 3
Complete response letters: 0
Medicare spending, 2025: $505M
First approved in the EU: Sep 7, 1999
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Fiasp, new approvalDrugs in new dosage forms indicated for the treatment of diabetes mellitus in cases where insulin therapy is indicated. · Novo Nordisk Pharma Ltd. · Sep 20, 2019
NovoRapidA drug with a new route of administration and a new dosage. · Novo Nordisk Pharma Ltd. · Jun 22, 2012
NovoRapid, new approvalDrugs with a new dosage and in an additional dosage form indicated for the treatment of diabetes mellitus where insulin therapy is indicated. · Novo Nordisk Pharma Ltd. · Sep 18, 2009
NovoRapid, new approvalDrugs with a new dosage indicated for the treatment of diabetes mellitus where insulin therapy is indicated. · Novo Nordisk Pharma Ltd. · Aug 20, 2009
Clinical Trials
19 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
